Alan Carr

Alan Carr, Alethia Young, Analyst Color, Analyst Ratings, Benzinga, Biotech, Cantor Fitzgerald, Earnings, General, Geoffrey Porges, GILD, Guidance, Health Care, Matthew Harrison, morgan-stanley, Needham, News, Raymond James, Reiteration, remdesivir, Steven Seedhouse, SVB Leerink, Top stories, US3755581036

Gilead Analysts Downplay Q2 Miss Amid Remdesivir’s COVID-19 Opportunity

Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations.
The Gilead Analysts

Latest Ratings for GILD
DateFirmActionFromTo Jul 2020Credit SuisseMaintainsNeutral Jul 2020Morgan StanleyMaintainsEqu…